Elevance Health is working through a Medicaid-driven margin reset, but Q2 results, raised guidance, and Carelon growth point to a resilient earnings recovery. The stock looks attractively valued for a large managed-care platform with scale, cash flow, and multiple growth levers.
Elevance Health(ELV) looks like a high-quality managed-care operator that is moving through a margin repair year rather than a broken-business year. The core case rests on four hard facts. First, Q2 2026 adjusted diluted EPS came in at $7.45 on $49.8B of operating revenue, and management raised full-year adjusted EPS guidance to at least $27. Second, management said it remains confident in returning to at least 12% adjusted EPS growth in 2027 off the 2026 baseline. Third, the company still generates scale-level cash flow, with trailing free cash flow of $5.406B and a raised 2026 operating cash flow outlook of at least $6B. Fourth, ELV trades at 15.873x forward earnings and 18.0843x trailing earnings, which is not demanding for a business with national scale, Blue Cross Blue Shield positioning, and a growing services platform in Carelon.
The investment debate is not whether Elevance has a moat. It does. The real debate is whether Medicaid pressure, elevated medical cost trend, and thinner recent net margins deserve a lasting valuation discount. The evidence argues for some discount, but not a severe one. Revenue reached $200.416B, medical membership remained 44.9M in Q2 2026, and Carelon revenue rose 6% YoY to $19.2B in the quarter. That gives ELV multiple earnings levers beyond any single government program line.
For a balanced, moderate-risk investor with a medium-term horizon, ELV fits best as a Buy on operational resilience and earnings recovery potential, not as a deep contrarian gamble. The stock’s beta of 0.683 also supports that profile. This is a large insurer trying to turn cost control into renewed earnings growth. In managed care, that is usually a better setup than chasing a perfect story at a perfect moment, because perfect stories in this industry tend to get repriced quickly.
Elevance Health(ELV) is a U.S. managed-care company headquartered in Indianapolis, with 96,129 employees and operations across all 50 states, D.C., and Puerto Rico through subsidiaries. The company changed its name from Anthem to Elevance Health in June 2022, but the operating logic remains familiar: collect premiums, manage medical costs, contract with providers, and increasingly use pharmacy, behavioral, digital, and care-management tools to improve margins and retention.
The company operates through four reported segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment remains the economic engine. In 2025, Health Benefits segment revenue was $167.094B, equal to 84.8% of total revenue before eliminations. Carelon Services segment revenue was $71.716B, or 36.4% of total before eliminations, showing how large the services layer has become inside the enterprise.
ELV’s brands include Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon. The Blue Cross Blue Shield affiliation matters because it gives the company entrenched local distribution and provider-network relevance in many markets. The 10-K states that being a BCBS licensee provides significant market value, especially for large multi-state employer groups, and supports the BlueCard program that extends network utility across states.
Scale is the first thing to understand here. Elevance ended Q2 2026 with 44.9M medical members, after 45.2M medical members at Dec. 31, 2025. That membership base supports pricing power, claims data depth, provider contracting leverage, and administrative efficiency. In insurance, scale is not glamorous, but it is often the difference between absorbing cost shocks and being run over by them.
Health Benefits is ELV’s core segment and includes commercial, Medicare, Medicaid, Individual ACA, BlueCard, FEP, and fee-based administrative services. In Q2 2026, Health Benefits revenue was $42.7B, up 3% YoY. Management said higher premium yields drove growth, partly offset by lower membership in Medicare Advantage, Medicaid, and Employer Group risk products.
Within Health Benefits, Medicaid is the pressure point. Management kept its full-year Medicaid operating margin outlook at approximately -1.75% and called 2026 the trough year for Medicaid margins. On the Q2 call, CFO Mark Kaye said cost drivers remained elevated in behavioral health, specialty pharmacy, outpatient surgery, and emergency department utilization. He also said rate updates received during the quarter were higher than anticipated, and management expects the second-half Medicaid margin profile to improve from Q2.
Medicare Advantage improved meaningfully in Q2 2026. Management said disciplined plan design, a more focused product mix, favorable claims experience, and care-management programs support a path to at least a 2% operating margin this year. That matters because Medicare Advantage has been a margin minefield across the industry. ELV is not claiming victory across the board, but it is showing that repricing and product discipline are working.
The Individual ACA business also helped Q2. Management said quarter favorability reflected the higher mix of bronze plans and favorable final 2025 CMS risk adjustment results. It now expects to end 2026 with at least 1M Individual ACA members. That is useful because ACA can offset some Medicaid attrition, though management explicitly avoided extrapolating early-year favorability too far.
Commercial group performance was in line with expectations, with elevated cost trend but pricing discipline intact. CEO Gail Boudreaux said employers are looking for affordability, navigation, behavioral health, and digital engagement capabilities, and that ELV’s integrated medical and pharmacy model is resonating. In plain English, ELV is trying to sell more than an insurance card. It wants to sell cost control wrapped in a member-experience pitch.
Carelon is the second major pillar. In Q2 2026, Carelon revenue was $19.2B, up 6% YoY. The company said CarelonRx saw early progress in the 2027 selling season, while Carelon Services continued investing in newer risk-based programs that take time to mature. That means near-term earnings drag in exchange for longer-term diversification and margin tools.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
ELV does not have a single flagship product in the way a software or device company does. Its flagship economic product is the integrated health-plan platform tied to commercial, Medicare, Medicaid, and ACA coverage, increasingly linked with Carelon services. The most important current product expression is the integrated medical and pharmacy offering that management repeatedly highlighted in Q2 2026.
That integrated offering matters because pharmacy is no longer a sidecar. Specialty drug trend, formulary management, home delivery, infusion, claims adjudication, and rebate administration all shape total cost of care. The 10-K says CarelonRx includes core pharmacy services plus ambulatory infusion centers added through Paragon Healthcare. Management also said early progress in the 2027 selling season reflects demand for the integrated medical and pharmacy offering.
On the member side, Sydney Health and Concierge Care are key engagement products. Gail Boudreaux said these tools use data, digital tools, and care teams to help members navigate benefits, schedule care, manage conditions, and close gaps in care. For an insurer, better navigation is not just a service feature. It is a claims-management tool disguised as convenience.
HealthOS is another important product layer. Management said it helps providers review care plans earlier, reduce delays, and support better clinical decisions. In deployed health systems, ELV said it has seen significant reductions in avoidable denials, documentation requests, and administrative friction. That is valuable because provider abrasion eventually turns into cost, network strain, or both.
CareBridge stands out inside Carelon’s home-based and complex-care model. Management said CareBridge can generate medical savings in the mid-teens for members and is expanding to new markets. That is one of the cleaner examples in the current ELV story where management tied a named capability to a quantified outcome.
ELV’s moat is structural first and digital second. The structural layer includes BCBS licenses, scale, provider relationships, national reach, and diversified exposure across commercial, Medicare, Medicaid, and services. The digital and operational layer is increasingly built through Carelon, HealthOS, Sydney Health, payment integrity tools, and AI-enabled cost management.
Management’s Q2 commentary was unusually specific on where innovation is aimed. Gail Boudreaux said the company is accelerating investments in earlier detection of medical cost trend, more precise clinical intervention, simpler member experience, and better provider connectivity. She said ELV has compressed months of work into days in some cost-detection workflows. That is exactly the kind of operational speed an insurer needs when utilization shifts faster than annual pricing cycles.
Carelon adds another edge because it gives ELV more control over the healthcare spend stack. The 10-K describes Carelon Services as integrating physical, behavioral, pharmacy, and social-care capabilities, while CarelonRx handles pharmacy services and specialty management. That creates a tighter feedback loop between claims, clinical intervention, utilization management, and member engagement than a pure-play insurer would have.
The company also has evidence that some of these capabilities are producing measurable savings. Management said behavioral health programs have delivered 10% cost savings on average through stronger engagement and fewer adverse events. It also said CareBridge can produce mid-teens medical savings. Those are not broad promises. They are named examples of where the services platform is meant to justify its investment.
This does not make ELV a technology company in disguise. It remains a managed-care company. But in this industry, better data, earlier intervention, and lower provider friction can be the difference between a 2% margin business and a 4% margin business. That spread is small in percentage terms and huge in earnings terms.
For ELV, operations matter more than any traditional supply chain. The company’s operating machine includes provider contracting, claims adjudication, pharmacy networks, care management, digital engagement, and capital movement across regulated subsidiaries. The Q2 2026 numbers show that machine is still functioning well enough to support raised guidance, even while some lines remain under pressure.
Operating revenue totaled $49.8B in Q2 2026, up 0.8% YoY. Benefit expense ratio was 89.7%, up 80 bps YoY, while adjusted operating expense ratio was 11.0%. Those figures show the core challenge clearly: medical costs remain elevated, and ELV has to offset that through pricing, mix, and administrative discipline.
Days in claims payable were 45.4 days as of June 30, 2026, up 2.9 days YoY. That is a useful operating metric because it reflects claims timing and reserve dynamics. Operating cash flow was $1.9B in Q2, and management raised full-year operating cash flow guidance to at least $6B. The quarter also included timing effects from a state Medicaid pass-through payment received in Q2 and remitted in July.
The company also made an initial remittance to CMS of $342M in Q2 related to a previously discussed matter. Management said that as of July 9, 2026, CMS had confirmed sanctions would not be imposed and the matter was closed. That removes a meaningful operational overhang in Medicare Advantage.
On network and market management, ELV is pruning where economics do not work. Management said it recently reached a mutual agreement to exit the D.C. Medicaid market and expects to exit additional Medicaid markets over the next 12 to 18 months where it does not see a path to sustainable performance. That is not retreat for its own sake. It is capital discipline in a business where bad contracts can linger like a slow leak.
ELV operates in a very large and still growing market. The U.S. health and medical insurance market is estimated at $1.65T in 2026 and projected to reach $2.15T by 2031, implying 5.37% CAGR. The healthcare payer services market is growing faster, with managed care identified as the fastest-growing application segment at 10.29% CAGR through 2031. That split matters because ELV is exposed to both premium revenue and services revenue through Carelon.
Employer-sponsored coverage remains the anchor of the market, while Medicare Advantage remains a major growth engine. Individual and family plans are also growing, helped by subsidy structures and coverage shifts after Medicaid redeterminations. ELV is positioned across all three. That diversification is one reason the company can absorb pressure in one line without losing the whole earnings year.
Industry demand also supports ELV’s strategy. Employers are managing benefit affordability aggressively, and payer technology spending is increasingly focused on privacy, security, AI, health data platforms, and cost control. ELV’s emphasis on HealthOS, digital engagement, payment integrity, and integrated pharmacy and care management fits that direction.
At the same time, the industry is not a clean growth story. Medical cost inflation, utilization pressure, and regulatory complexity can eat margin faster than premium growth can replace it. ELV’s own Q2 benefit expense ratio of 89.7% shows that the market opportunity is large, but so is the cost pressure required to serve it.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
ELV serves a broad customer base across individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid, and FEP members. The 10-K says product development and marketing efforts are tailored to the differing needs of these customer groups, including educational and public entities, labor groups, national employers, and state-run programs serving low-income and underserved markets.
That breadth matters because customer economics vary widely. Commercial employer clients care about affordability, network breadth, navigation, and employee support. Medicare members care about plan design, benefits stability, and care coordination. Medicaid contracts depend heavily on rate adequacy, acuity, and state policy. ACA members are more sensitive to premium, subsidy, and plan-metal mix, which management highlighted through the higher bronze-plan mix in 2026.
Distribution also varies by customer type. The 10-K says individual, Medicare, and some smaller employer products are sold through direct marketing, independent agents, brokers, and retail partnerships. Larger commercial products are generally sold through brokers or consultants working with ELV’s in-house sales force. Digital platforms are increasingly supplementing those channels.
The customer profile supports stickiness. BCBS branding helps with large employers and local trust. Carelon services help deepen relationships beyond the insurance policy itself. And the company’s 93.389% institutional ownership suggests the market still sees ELV as a core, investable franchise rather than a speculative turnaround.
ELV competes with UnitedHealth(UNH), CVS Health(CVS), The Cigna Group(CI), Humana(HUM), Centene(CNC), and Molina Healthcare(MOH), with the competitor set shifting by line of business. UnitedHealth is the scale benchmark. Humana is especially relevant in Medicare Advantage. Centene is a key competitor in Medicaid and ACA. Cigna and CVS are important in commercial and integrated services.
ELV’s relative strengths are scale, BCBS positioning, diversified payer mix, and the Carelon platform. The company is stronger than smaller regional plans and generally more diversified than narrower government-program specialists. The main relative weakness versus UNH is obvious: ELV is large, but UNH is still larger, broader, and more vertically integrated.
Carelon is central to ELV’s competitive response. The industry trend is toward vertical integration into PBM, behavioral health, care management, and data services. ELV is not standing still on that front. Q2 2026 Carelon revenue of $19.2B, up 6% YoY, shows the services arm is already material rather than aspirational.
Competition in managed care is usually won on pricing discipline, network quality, bid accuracy, and cost trend management, not on flashy product launches. ELV’s recent results suggest it is executing better in Medicare Advantage and ACA than the market feared, while still working through Medicaid pressure. That puts it in the middle of the pack on narrative and near the top tier on franchise quality.
ELV’s macro exposure is mostly domestic and policy-driven rather than geopolitical in the classic sense. The company derives the majority of revenue inside the U.S., and the 10-K says only an immaterial amount comes from activities outside the U.S. and Puerto Rico. The real macro variables are healthcare cost inflation, labor costs, specialty drug trend, employment conditions, and federal and state reimbursement policy.
Government exposure is significant. The 10-K says approximately 32% of consolidated revenue came from agencies of the U.S. government in 2025, versus 31% in 2024 and 29% in 2023. That supports scale and demand stability, but it also means ELV is exposed to CMS rules, Medicaid rate cycles, ACA subsidy policy, and Medicare Star Ratings.
The post-pandemic Medicaid redetermination cycle remains a major industry force. ELV has already felt that through membership attrition and higher acuity among remaining members. Management said the largest earlier issue was the acuity reset as lower-cost members exited the program, and that the dynamic is now moderating. That is encouraging, but it still leaves 2026 as a repair year for Medicaid margins.
Another macro factor is healthcare inflation itself. The company’s 10-K flags advances in medical technology, prescription drug utilization, demographic trends, and regulatory changes as contributors to rising healthcare costs. In this business, inflation can lift premium revenue and crush margins at the same time. ELV’s operating challenge is to make sure the first effect does not arrive slower than the second.
Trailing free cash flow reached $5.406B, while management lifted 2026 operating cash flow guidance to at least $6B, underscoring solid liquidity through the margin reset.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 adjusted diluted EPS was $7.45 on $49.8B of operating revenue, and full-year adjusted EPS guidance was raised to at least $27.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management still expects at least 12% adjusted EPS growth in 2027 off the 2026 baseline, signaling confidence that the earnings trough is temporary.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ELV trades at 15.873x forward earnings and 18.0843x trailing earnings, a modest multiple for a national managed-care platform with Carelon diversification.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s valuation framework places the stock at $410 fair value, with upside to $470 and $530 only if the recovery stalls less than expected.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Elevance Health(ELV) is not a perfect story, and that is exactly why it remains interesting. The company has real pressure in Medicaid, visible margin compression over the last several years, and a business model that lives under heavy regulatory scrutiny. But it also has nearly $200B in revenue, 44.9M medical members, a large and growing Carelon platform, strong institutional sponsorship, and management confident enough to raise guidance and point to at least 12% adjusted EPS growth in 2027.
The stock’s appeal is not based on hype. It is based on a large franchise proving that its cost controls, product discipline, and service integration are working well enough to rebuild earnings power. Q2 2026 adjusted EPS of $7.45, raised full-year adjusted EPS guidance of at least $27, and operating cash flow guidance of at least $6B are concrete signs of that rebuild.
For moderate-risk investors, the right stance is constructive but selective. ELV deserves a Buy rating with a fair value estimate of $410 because the business has enough quality and enough recovery evidence to justify upside from a reasonable entry, but not enough clean margin expansion yet to justify paying any price. In other words, this is a disciplined healthcare compounder, not a lottery ticket. That is usually the better kind.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Elevance didn't get punished for missing the quarter; it got punished because the market no longer trusts the quality of the beat. Raised guidance matters less when Medicaid costs are still rising, membership is slipping, and management is calling 2026 the low point for profitability.
Elevance Health beat EPS and revenue, but the stock drops as investors focus on Medicaid margin pressure, membership declines, and the quality of the upside. This deep-dive breaks down the quarter’s mix, guidance, Carelon integration, and why a clean beat still failed to win the market.
Elevance Health Inc. (ELV) falls 10.0% even after earnings beats, as investors react to the latest results and outlook.